ConductScience.org, home
Papers
API referenceFor AI assistants

Paper · 38675715

Predictive and Prognostic Biomarkers and Tumor Antigens for Targeted Therapy in Urothelial Carcinoma.

Eturi A and 3 others. Molecules, 2024. Cited by 18 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Download JSON
Cite this record

ConductScience Library. Predictive and Prognostic Biomarkers and Tumor Antigens for Targeted Therapy in Urothelial Carcinoma. Papers, record 38675715. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/38675715

On this page

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Predictive and Prognostic Biomarkers and Tumor Antigens for Targeted Therapy in Urothelial Carcinoma.
PubMed
Journal
Molecules
PubMed
Year
2024
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
18
iCite
Relative citation ratio, by iCite
2.83, provisional
iCite
Revised in PubMed
2026-09-22
PubMed

Authors4

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Eturi AAdityahttps://orcid.org/0009-0005-4702-2017
2Bhasin AAmman
3Zarrabi KKKevin Khttps://orcid.org/0000-0002-9351-2317
4Tester WJWilliam Jhttps://orcid.org/0000-0002-5766-0195

Source PubMed

Topics8

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Antigens, NeoplasmMajor topic
Biomarkers, TumorMajor topic
Molecular Targeted TherapyMajor topic
Urinary Bladder NeoplasmsMajor topic
Urologic NeoplasmsMajor topic
Humans
Carcinoma, Transitional Cell
Prognosis

Source PubMed

Grants0

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

None in this release.

Trials0

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

None in this release.

Comments and corrections0

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

None in this release.

References95

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
136,383,379Analysis of MRE11 and Mortality Among Adults With Muscle-Invasive Bladder Cancer Managed With Trimodality Therapy.JAMA Netw Open2022https://conductscience.org/library/papers/36383379PubMed
231,340,094Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma.N Engl J Med2019https://conductscience.org/library/papers/31340094PubMed
327,751,785Circulating biomarkers to guide systemic therapy for urothelial carcinoma.Urol Oncol2016https://conductscience.org/library/papers/27751785PubMed
437,016,296Blood-based liquid biopsy: insights into early detection, prediction, and treatment monitoring of bladder cancer.Cell Mol Biol Lett2023https://conductscience.org/library/papers/37016296PubMed
524,714,082Activity of CEP-9722, a poly (ADP-ribose) polymerase inhibitor, in urothelial carcinoma correlates inversely with homologous recombination repair response to DNA damage.Anticancer Drugs2014https://conductscience.org/library/papers/24714082PubMed
636,186,672Immunotherapy With Checkpoint Inhibitors in FGFR-Altered Urothelial Carcinoma.Clin Med Insights Oncol2022https://conductscience.org/library/papers/36186672PubMed
732,532,789Nivolumab in Patients with Advanced Platinum-resistant Urothelial Carcinoma: Efficacy, Safety, and Biomarker Analyses with Extended Follow-up from CheckMate 275.Clin Cancer Res2020https://conductscience.org/library/papers/32532789PubMed
830,343,614Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients With Muscle-Invasive Urothelial Bladder Carcinoma (PURE-01): An Open-Label, Single-Arm, Phase II Study.J Clin Oncol2018https://conductscience.org/library/papers/30343614PubMed
925,459,391Multicentre randomised phase II trial of gemcitabine+platinum, with or without trastuzumab, in advanced or metastatic urothelial carcinoma overexpressing Her2.Eur J Cancer2015https://conductscience.org/library/papers/25459391PubMed
1012,208,738Transcription-coupled nucleotide excision repair as a determinant of cisplatin sensitivity of human cells.Cancer Res2002https://conductscience.org/library/papers/12208738PubMed

1 to 10 of 95

See all 95 references

Cited by12

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 18 citations.

PMIDTitleJournalYearIn PapersSource
42,490,199DNA damage response pathway alterations in urothelial carcinoma: a road to precision oncology or a dead-end street?Oncologist2026https://conductscience.org/library/papers/42490199PubMed
42,390,654HER2 assessment in urothelial carcinoma: standardization challenges and the path forward.Cancer Metastasis Rev2026https://conductscience.org/library/papers/42390654PubMed
41,649,558[Neoadjuvant therapy and complete response of muscle-invasive bladder cancer: may the urinary bladder be preserved?]Urologie2026https://conductscience.org/library/papers/41649558PubMed
41,168,440Optimizing local control in the surgical management of bladder cancer.Nat Rev Urol2026https://conductscience.org/library/papers/41168440PubMed
40,591,027Neoadjuvant treatment patterns and biomarker selection in muscle-invasive bladder cancer.Discov Oncol2025https://conductscience.org/library/papers/40591027PubMed
40,526,099Optimizing enfortumab vedotin plus pembrolizumab therapy.Oncotarget2025https://conductscience.org/library/papers/40526099PubMed
40,427,030Investigating the Genetic Links Between Immune Cell Profiles and Bladder Cancer: A Multidisciplinary Bioinformatics Approach.Biomedicines2025https://conductscience.org/library/papers/40427030PubMed
39,683,926Adsorption Behaviors of ctDNA and Biological Activities Based on Polyvinyl Alcohol/Polyethylene Glycol/Quaternized Chitosan Composite Hydrogel.Molecules2024https://conductscience.org/library/papers/39683926PubMed
39,678,505Bladder cancer biomarkers: current approaches and future directions.Front Oncol2024https://conductscience.org/library/papers/39678505PubMed
39,596,194Use of 3' Rapid Amplification of cDNA Ends (3' RACE)-Based Targeted RNA Sequencing for Profiling of Druggable Genetic Alterations in Urothelial Carcinomas.Int J Mol Sci2024https://conductscience.org/library/papers/39596194PubMed

1 to 10 of 12

See all 12 cited by

Genes4

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
CD27429,126PubTator's text mininghttps://conductscience.org/library/genes/29126NCBI Gene
EGFR1,956PubTator's text mininghttps://conductscience.org/library/genes/1956NCBI Gene
ERBB22,064PubTator's text mininghttps://conductscience.org/library/genes/2064NCBI Gene
PARP1142PubTator's text mininghttps://conductscience.org/library/genes/142NCBI Gene

Drugs0

The drugs whose trials, in the Pipelines release, list the paper.

None in this release.

Data0

The data bank entries PubMed's record names. Trial numbers are under Trials.

None in this release.

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/38675715

GET https://conductscience.org/api/papers/v1/38675715/references?page=2

API referenceFor AI assistants